Pracovní skupina České Pneumologické a ftizeologické společnosti navrhla jednoduchou klasifikaci pacientů s post-COVID postižením. Tato klasifikace rozděluje pacienty do čtyř skupin (A-B-C-D) na základě přítomnosti nebo absence: 1) subjektivních respiračních symptomů (dušnost, kašel, bolesti na hrudi) a 2) objektivních známek plicního postižení (pokles TLco, latentní respirační nedostatečnost, postižení struktury plic dle skiagramu nebo HRCT hrudníku) v období 3 a více měsíců od potvrzené diagnózy COVID-19.
- MeSH
- lidé MeSH
- postakutní syndrom COVID-19 * diagnóza patologie terapie MeSH
- pozorovací studie jako téma MeSH
- prospektivní studie MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- abstrakt z konference MeSH
- MeSH
- COVID-19 komplikace MeSH
- lidé MeSH
- postakutní syndrom COVID-19 * patologie terapie MeSH
- respirační funkční testy MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- abstrakt z konference MeSH
We stratified post-COVID patients into four newly established clinical groups based on the presence or absence of at least one subjective respiratory symptom and at least one objective sign of pulmonary involvement. Nearly half of outpatients and one third of hospitalized post-COVID patients had objective signs of pulmonary involvement without accompanying subjective respiratory symptoms three months after diagnosis.
- MeSH
- COVID-19 * komplikace epidemiologie patologie MeSH
- hospitalizace MeSH
- lidé MeSH
- plíce patofyziologie MeSH
- prospektivní studie MeSH
- SARS-CoV-2 MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Geografické názvy
- Česká republika MeSH
Drug-induced cardiotoxicity is a serious problem associated with the administration of many drugs. MicroRNAs (miRNAs) have been reported to be affected by drugs and other xenobiotics, and the potential of miRNAs as biomarkers and diagnostic tools has been considered. In recent years, an association of certain miRNAs with the cardiotoxicity of some drugs, namely anthracyclines, bevacizumab, cyclosporine A and isoprenaline, has already been found. This review article summarizes available information about the changes in miRNA levels induced by cardiotoxic drugs. Three aspects are discussed: the altered expression of miRNAs in the heart upon treatment with cardiotoxic drugs, circulating miRNAs as promising early biomarkers of cardiotoxicity, and the potential of miRNAs in the prevention and/or attenuation of drug-induced cardiotoxicity. The targeted changes in the level of certain miRNAs by antagomiRs and miRNA mimics are also described and evaluated. In addition, the cardioprotective mechanism of various natural compounds via their effect on miRNA levels are examined.
Cardiotoxicity is a serious adverse reaction to cancer chemotherapy and may lead to critical heart damage. Imatinib mesylate (IMB), a selective tyrosine kinase inhibitor, is sometimes accompanied by severe cardiovascular complications. To minimize risk, early biomarkers of such complications are of utmost importance. At the present time, microRNAs (miRNAs) are intensively studied as potential biomarkers of many pathological processes. Many miRNAs appear to be specific in some tissues, including the heart. In the present study we have explored the potential of specific miRNAs to be early markers of IMB-induced cardiotoxicity. Doxorubicin (DOX), an anthracycline with well-known cardiotoxicity, was used for comparison. NMRI mice were treated with IMB or DOX for nine days in doses corresponding to the highest recommended doses in oncological patients, following which plasmatic levels of miRNAs were analyzed in miRNA microarrays and selected cardio-specific miRNAs were quantified using qPCR. The plasmatic level of miR-1a, miR-133a, miR-133b, miR-339, miR-7058, miR-6236 and miR-6240 were the most different between the IMB-treated and control mice. Interestingly, most of the miRNAs affected by DOX were also affected by IMB showing the same trends. Concerning selected microRNAs in the hearts of individual mice, only miR-34a was significantly increased after DOX treatment, and only miR-205 was significantly decreased after IMB and DOX treatment. However, no changes in any miRNA expression correlated with the level of troponin T, a classical marker of heart injury.
- MeSH
- doxorubicin toxicita MeSH
- imatinib mesylát farmakologie MeSH
- mikro RNA krev genetika metabolismus MeSH
- myši MeSH
- regulace genové exprese účinky léků MeSH
- srdce účinky léků MeSH
- transkriptom účinky léků MeSH
- troponin T krev genetika metabolismus MeSH
- zvířata MeSH
- Check Tag
- myši MeSH
- ženské pohlaví MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- Publikační typ
- abstrakt z konference MeSH
- Publikační typ
- abstrakt z konference MeSH
